Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours

Next Previous
Search
Trial Profile

A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPN 60090 (Primary) ; Paclitaxel; Pembrolizumab
  • Indications Anal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Ipsen

    • Most Recent Events

    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 29 Jan 2021 Status changed from recruiting to discontinued due to following an internal portfolio review, Ipsen has made the decision to terminate studyD-US-60090-001. Ipsen would like to highlight that early termination was not due to any safetyor tolerability issues with IPN60090.
    • 26 Jun 2019 Planned number of patients changed from 228 to 236.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top